There are currently 434 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening
NCT05665660
Recruiting
The goal of this study is to evaluate the relative benefits of an intervention to promote breast cancer screening among women in the White Mountain Apache (WMA) community. Women will be randomized to receive CARE, a culturally tailored mammography education module, or CARE+COACH, which is the CARE education module plus access to an Apache paraprofessional women's health coach (i.e., patient navigator). The CARE intervention was developed through a community-based participatory research process.... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
07/21/2025
Locations: Center for Indigenous Health, Whiteriver, Arizona
Conditions: Breast Cancer
Register for Updates
WashU DIEP Flap Video and Patient Understanding Improvement
NCT06864754
Recruiting
Patients will complete a survey before and after watching the WashU DIEP Flap Video at their pre-operative standard of care visit, and a third survey at their post-operative standard of care visit. These surveys will use questions from SILS, APAIS, PEMAT, and AIM/IAM to assess the patient's health literacy, demographics questions, and questions concerning patient understanding and anxiety surrounding the procedure. The purpose of the post-op survey will be to assess how well the video set expect... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Cancer
Register for Updates
BREAST Choice Decision Tool R21
NCT06817226
Recruiting
Breast reconstruction is a critical component of breast cancer treatment because it restores quality of life and body image after mastectomy. However, Spanish-speaking Latina women are significantly less likely to undergo reconstruction (13.5% vs. 41% for non-Latina White or highly acculturated Latina), meet with a reconstructive surgeon (18.1% vs. 72.6% for non-Latina White), or receive adequate information. Spanish-speaking Latina breast cancer survivors who do not have reconstruction experien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2025
Locations: The University of North Carolina, Chapel Hill, North Carolina
Conditions: Breast Cancer
Register for Updates
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394
Recruiting
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Dana-Farber Cancer Institute ( Site 0050), Boston, Massachusetts +10 locations
Conditions: Breast Neoplasms, Breast Cancer
Register for Updates
Study to Assess Clinical Activity of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483
Recruiting
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut +18 locations
Conditions: Breast Cancer
Register for Updates
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379
Recruiting
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Research Site, Daphne, Alabama +355 locations
Conditions: Breast Cancer
Register for Updates
A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
NCT05812924
Recruiting
The purpose of this study is to determine whether platelet rich plasma (PRP) injections to the vulva and vagina will improve symptoms of genitourinary syndrome of menopause (GSM) in breast cancer patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, Genitourinary Syndrome of Menopause
Register for Updates
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521
Recruiting
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design. The study details and doses of Part 2 (dose-optimization)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: University of Southern California, Los Angeles, California +2 locations
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, NUT Carcinoma
Register for Updates
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
NCT06371768
Recruiting
The purpose of this study is to determine the effectiveness of a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and engage in recommended follow-up care.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
07/18/2025
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Cancer, Breast Cancer, Colorectal Cancer, Sarcoma, Lymphoma, Testicular Cancer
Register for Updates
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
NCT05056077
Recruiting
This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors. Studies indicate that people with a history of cancer whose nutrition and physical activity habits are consistent with the American Cancer Society's Nutrition and Physical Activity Guidelines may have longer disease-free survival. The four different intervention components may help patients with a history of cancer adopt recommended health... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Rectal Cancer, Prostate Cancer, Renal Cell Carcinoma, Kidney Cancer
Register for Updates
ERAS Protocols in Breast Conserving Surgery
NCT06938581
Recruiting
Enhanced Recovery After Surgery (ERAS) protocols have been of increasing interest in the surgical community for decades. The emphasis has been development of protocols to maximize pain control post-operatively without the use of opioids. While this approach has been studied extensively in the oncology surgery literature, little data exists on the utility of ERAS protocols in the setting of breast conserving surgery (BCS), which is a type of surgery to remove breast cancer while saving as much of... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
07/17/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Breast Cancer, Postoperative Recovery
Register for Updates
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
NCT06123286
Recruiting
Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics we often find that patients tend to be more receptive to taking a supplement as opposed to an additional medication. Further, both Tart Cherry concentrate and fish oil have beneficial properties for helping with joint stiffness in general, in addit... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California +1 locations
Conditions: Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Register for Updates